The low expression of DMBT1 gene in prostate cancer and its clinical significance

DU Jun-hua,JIANG Hao-wen,GUAN Ming,TONG Shi-jun,DING Qiang,YU De-xin
DOI: https://doi.org/10.3969/j.issn.1009-8291.2011.02.019
2011-01-01
Abstract:Objective To identify the genes that might be regulated by methylation during the prostate tumorigenesis,detect the expression of the genes in prostate cancer cell lines and tissues,and evaluate the potential correlation between the gene expressions and clinical/pathologic features.Methods We used the Whole Human Genome Oligo Microarray to screen the treated cells and the controlled groups to identify the genes which restored expression after anti-methylation.Then we detected the expressions of DMBT1 in mRNA and protein levels by real-time quantitative PCR and western blot in prostate cancer cell lines(LNCaP & PC-3) and prostatic tissues from 16 benign lesions and 39 carcinomas.Results The expression of DMBT1 gene(Deleted in Malignant Brain Tumor) was significantly up-regulated in treated PC-3 cell lines than in controlled cell lines;however,no similar expression change was observed in treated or controlled LNCaP cell lines.Compared to the normal prostatic tissues,mRNA and protein expressions of DMBT1 gene were significantly down-regulated in whole prostate cancer tissue samples.The statistical results showed that the expressions of DMBT1 were correlated to clinical stage and osseous metastasis,but not to patient age,PSA level and tumor grades.Conclusions The DMBT1 gene is confirmed to be a potential biomarker in identifying hormonal independent subgroup from hormonal dependent prostatic carcinomas,as well as the prognostic value with its correlation to clinical stage and tumor grades.It is necessary to elucidate the regulation mechanism of DMBT1 and its contribution in cell physiology and tumorigenesis.
What problem does this paper attempt to address?